FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart
25 October 2012 | By Novo Nordisk
“This meeting will focus on the cardiovascular safety of two products..."
List view / Grid view
25 October 2012 | By Novo Nordisk
“This meeting will focus on the cardiovascular safety of two products..."
19 October 2012 | By Novo Nordisk
Tresiba® and Ryzodeg® receive positive opinions...
19 October 2012 | By Novo Nordisk
Japan’s PMDA has published an assessment report of Tresiba®...
16 October 2012 | By Novo Nordisk
Novo Nordisk announced the submission of the regulatory application for turoctocog alfa...
5 October 2012 | By Novo Nordisk
4/5 people with type 2 diabetes have experienced self-treated hypoglycaemia...
3 October 2012 | By Novo Nordisk
"We know from clinical practice that liraglutide is highly effective..."
2 October 2012 | By Novo Nordisk
Than insulin glargine in a 2-year study investigating people with type 2 diabetes...
24 September 2012 | By Novo Nordisk
Novo Nordisk invests an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing....
24 September 2012 | By Novo Nordisk
Novo Nordisk has been ranked number four on the Science 2012 Top Employer list – up from ninth place last year...
9 August 2012 | By Novo Nordisk
Sales grew 17% driven by Victoza®, NovoRapid® and Levemir®...
18 July 2012 | By Novo Nordisk
Meeting scheduled to discuss the NDA for the ultra-long-acting insulin degludec & insulin degludec/insulin aspart....
In this PAT In-Depth Focus: Process analytics experiences in biopharmaceutical manufacturing; Correlation between powder rheology data and processability in solid dosage form manufacturing; Expert industry users of process analytical technologies for pharmaceuticals pose questions for leading vendor experts of process analytical technology...
2 July 2012 | By Novo Nordisk
Novo Nordisk awarded the red dot Best of the Best prize for its next-generation insulin injection pen, the NovoPen® 5...
21 June 2012 | By Novo Nordisk
The decision to initiate the global phase 3 development programme for semaglutide announced...
20 June 2012 | By Novo Nordisk
Novo Nordisk is hosting a side-event during the UN conference, Rio+20, on sustainable development...